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ABSTRACT
Objectives: To identify factors that can affect compliance to treatment with neoplastic oral drugs in a group of  cancer patients. Methods:
Interviews were performed on 61 patients diagnosed with cancer and under anti-neoplastic oral therapy in a private hospital. The interviews
were carried out using instruments to assess compliance. Results: Most patients (95%) reported the oral treatment was not difficult. The
Morisky and Green Test were positive in 28% of  the patients. Factors that may affect following the treatment were significantly (p<0.05)
associated with the time variable; patients who presented more difficulty had more treatment time. Conclusions: Patients presented
positive attitudes toward the use of  this anti-neoplastic oral treatment therapy, however 28% were considered non-compliant in the Morisky
and Green Test.
Keywords: Neoplasms/drug therapy; Antineoplastic agents/therapeutic use; Patient compliance; Patient acceptance of health care
RESUMO
Objetivos: Identificar fatores associados à adesão ao tratamento com drogas de ação antineoplásica por via oral em pacientes com câncer.
Métodos: Foram entrevistados 61 pacientes com câncer sob terapia antineoplásica via oral em hospital particular, com a aplicação de
instrumentos para avaliar a adesão. Resultados: A maioria dos pacientes (95%) referiu que o tratamento oral não é difícil. O Teste Morisky
e Green foi positivo em 28% dos pacientes. Os fatores que podem influenciar a realização do tratamento se associaram de forma significativa
(p<0,05) com a variável tempo, os pacientes que apresentaram mais dificuldade, tinham mais tempo de tratamento. Conclusões: Os
pacientes apresentaram atitudes positivas frente ao tratamento com medicamentos antineoplásicos orais, porém foram considerados não
aderentes em 28% no Teste Morisky e Green.
Descritores: Neoplasias/quimioterapia, Antineoplásicos/uso terapêutico, Cooperação do paciente, Aceitação pelo paciente de cuidados de
saúde
RESUMEN
Objetivos: Identificar los factores asociados a la adhesión al tratamiento con drogas de acción antineoplásica por vía oral en pacientes con
cáncer.  Métodos: Fueron entrevistados 61 pacientes con cáncer sometidos a terapia antineoplásica por vía oral en un hospital particular, con
la aplicación de instrumentos para evaluar la adhesión. Resultados: La mayoría de los pacientes (95%) refirió que el tratamiento oral no es
difícil. El test Morisky y Green fue positivo en el 28% de los pacientes. Los factores que pueden influir en la realización del tratamiento se
asociaron de forma significativa (p<0,05) con la variable tiempo, los pacientes que presentaron más dificultad, tenían más tiempo de
tratamiento. Conclusiones: Los pacientes presentaron actitudes positivas frente al tratamiento con medicamentos antineoplásicos orales,
no obstante fueron considerados no adherentes en el 28% en el Test Morisky y Green.
Descriptores: Neoplasias/quimioterapia, Antineoplásicos/uso terapéutico, Cooperación del paciente, Aceptación por el paciente de cuidados
de salud
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INTRODUCTION
One of the greatest challenges of the
multiprofessional team assisting oncologic patients is to
obtain treatment compliance to oral antineoplastics.
Treatment compliance may be characterized as the extent
to which the individuals behavior agrees with the medical
or health advice in terms of  taking their medication,
changing their life style, and attending medical
appointments(1). Compliance may be affected by several
factors, which are associated with patients, treatment,
health services, beliefs, and life habits(2). Being aware of
these factors is an important tool for health professionals
who accompany the chronic patient evolution, especially
cancer patients.
Chronic diseases have a key role in the morbimortality
profile, and the need of prolonged or life-long
treatments becomes a challenge(3). In developed
countries, compliance to prolonged treatments is roughly
50%. This rate is even lower in developing countries,
due to a lack of financial resources(4). Cancer is a public
health issue in Brazil. It is the second cause of death,
preceded only by cardiovascular conditions. In 2003,
133000 deaths due to malignant neoplasias were reported
and more than half of them in the Southeast region(5).
The pharmaceutical industry has been developing
drugs to fight cancer with less toxic effects, which
patients can stand and handle well. They are orally
administered antineoplastic drugs. Of  the antineoplastic
drugs available in the international market, 5% are oral.
However, among the drugs studied 25% are oral(6). The
pros and cons of the new oral drugs are discussed by
several authors. The main advantages are: patient
convenience, no need of venous access, and less time
outside the household and work. Furthermore, some
medications are associated with fewer side effects,
causing quite an impact on patients quality of life. The
disadvantages include variation in medicine absorption,
patient compliance, handling side effects and medication
costs(7). Liu and colleagues have studied the preference
of 103 patients regarding chemotherapy and identified
that 90% preferred the treatment with oral drugs. The
reasons for the preferences included convenience (57%),
current interests or venous access difficulties (55%) and
greater control over the chemotherapy administration(8).
Taking these considerations into account, the present
study aimed to identify factors associated with treatment
compliance to oral antineoplastic drugs in a group of
cancer patients.
METHODS
This is an exploratory study that was carried out at a
private health institution, in the city of  São Paulo, after
approval from the Ethics Committee. The sample was
composed of 61 outpatients, randomly chosen. They
fulfilled the following criteria: age equal or over 18 years,
cancer diagnosis, under oral antineoplastic therapy and
willing to participate in the study by signing the full
consent form. Two instruments for data collection were
used and filled out by means of  interviews with the
outpatients. The Morisky and Green Test, originally
written in the English language(9) was translated and
validated for the Portuguese language(10). It evaluates
attitudes regarding treatment. It is made up of four
questions, described in Table 3, with Yes-No answers.
Yes stands for 0 and No stands for 1. The patient
compliance to treatment is considered for a score of
four points. With three or fewer points, the patient is
non-compliant. The other instrument used is made up
of questions related to factors or attitudes that may affect
patient treatment compliance. The answers are given in
a Likert-like scale with five levels: totally agree, partly
agree, indecisive, partly disagree or totally disagree, with
values of  5, 4, 3, 2 and 1 respectively. Hence, the
minimum score was 17 and the maximum was 85. The
patients whose overall answers did not exceed 34 were
regarded as having little or no difficulty in treatment.
Those with values over or equal to 35 showed difficulty.
These instrument questions, described in Table 4, were
elaborated considering these peoples professional
practice and also the treatment compliance thematic
regarding chronic diseases. The instrument was subjected
to a body of  judges so as to evaluate internal consistency,
pertinence, clearness and equal value, that is, all the
questions with similar values.
Data were also collected to characterize the
sociodemographic variables, related to medical diagnosis
and oral antineoplastic treatment.
The association between the qualitative variables
studied was evaluated with the chi-square test or
likelihood-ratio test or Fishers exact test. The quantitative
variables, shown as median and standard deviation, were
compared with the students t-test and the variables that
did not show normal distribution were evaluated with
the Wilcoxon signed-rank test. The p<0.05 values were
considered statistically significant.
RESULTS
Most studied patients (Table 1) were females, white,
married, with higher education and performing
administrative or commercial activities, followed by self-
employed individuals. The predominant age group was
the fifth decade and family income was more than five
minimum wages.
Gastrointestinal tract cancer was the most frequent,
followed by breast cancer. Concerning their finding out
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about the disease, around a third of the patients reported
that they felt bad and had routine medical exams
performed. Capecitabine was the most used oral
medication with antineoplastic effect, and the mean time
of  treatment was eight months. Regarding associated
treatments, most of them were subjected to endovenous
systemic chemotherapy, surgical procedure and
radiotherapy, and also alternative therapies such as
massage and religious rituals (Table 2).
According to Morisky and Green Test., 28% of
patients were observed as non-compliant, given that they
answered yes at least once. There was a statistically
significant association (p<0.05) among the test and
treatment time and the type of medication. Patientes
with positive values for Morisky and Green Test. were
being treated for a longer period. Patients who used
Mercaptopurine, Dexamethasone, Thalidomide and
hormone therapy drugs obtained positive values for
Morisky and Green Test; therefore, non-compliant to
treatment. Those using Imatinib and Temozolamide were
totally compliant to treatment (Table 3).
Analyzing the data in Table 4, the patients indicated
few drawbacks that may affect treatment compliance
to oral antineoplastics. Such fact can be observed when
they totally or partly disagreed with the following
questions: oral treatment is neither difficult nor
complicated and they knew how to take the medication
(95%); they do not have difficulty in remembering the
day to resume treatment (89%); the medication is not
difficult to swallow (88%); they do not need help to
take medicine, and they know whether the medication
should be taken before, during or after meals (87%);
they do not forget to take the medication (84%). Most
of them alleged not to forget to attend consultations
Table 1  Sociodemographic variables of  patients under
oral antineoplastic treatment
 
Variables N % 
Gender   
Female 39 64.0 
Male 22 36.1 
Ethnic group   
White 58 95.2 
Black 
Yellow 
1 
2 
1.6 
3.2 
Marital status   
Married 45 73.8 
Single 
Widow 
Separated 
8 
4 
4 
13.1 
6.6 
6.6 
Educational background   
Higher Education 49 80.4 
High School 8 13.1 
Ninth Grade 4 6.6 
Occupation   
Administrative, commercial activities 18 29.5 
Self-employed 16 26.2 
Homemaker 10 16.4 
Teaching Activity 8 13.1 
Visual Communication Activities 5 8.1 
Others* 4 6.5 
Income (minimum wages)   
1 to 5  9 15.8 
5 to 10  21 36.8 
15 to 20  
> 20  
9 
18 
15.8 
31.6 
Age (mean±SD, months) 54.8 ±15.6 
* others: chemist (2), sociologist (1), student (1)
Table 2  Patients with cancer under oral antineoplastic
treatment, according to medical diagnosis, treatment
performed, disease onset, treatment and chemotherapy
period
 
Variables N % 
Medical diagnosis   
Gastrointestinal Cancer 21 34.5 
Breast Cancer 17 27.9 
Glioma/Astrocytoma 8 13.1 
Leukemia 7 11.5 
Gynecological Cancer 3 4.9 
Prostate Cancer 2 3.3 
Genitourinary Cancer 1 1.6 
Lung Cancer 1 1.6 
Ocular Melanoma  1 1.6 
Discovery of disease   
Felt bad 20 32.8 
Routine medical exam 19 31.1 
Alterations, signals, specific symptoms 12 19.7 
Self-exam  10 16.4 
Oral Antineoplastic Medication   
Capecitabine 23 37.7 
Hormone therapy drugs* 15 24.5 
Temozolamide 7 11.5 
Erlotinibe 7 11.5 
Imatinib mesylate 7 11.5 
Mercaptopurine 2 3.3 
Associated treatments   
Endovenous Systemic Chemotherapy 44 72.1 
Surgery 43 70.5 
Radiotherapy 36 59.0 
Hormone therapy 3 4.9 
Immunotherapy 1 1.6 
Alternative Therapies 26 42.6 
Massage 9 34.6 
Religious Rituals 7 26.9 
Yoga, meditation 5 19.2 
Home-made medicine, teas 4 15.3 
Homeopathy 4 15.3 
Acupuncture 3 11.5 
Flower remedies 3 11.5 
Anthroposophic Medicine 3 11.5 
Disease onset 
(mean±SD, months) 37.1 ± 62.2 
Treatment time 
(mean±SD, months) 14.4 ± 25.1 
Oral chemotherapy time (mean±SD, 
months) 8.6 ± 14.8 
*Hormone therapy drugs: Anastrozol, Exemestane,
Bicalutamide, Tamoxifene
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Table 3 Morisky-Green Test and association with oral antineoplastic used and treatment time
 
Morisky-Green Test Yes No  
 N % N % p 
Have you ever forgotten to take your medication? 4 6.6 57 93.4  
Are you sometimes careless regarding the time to take your medication? 9 14.8 52 85.2  
When you feel good, do you quit taking medication? 1 1.6 60 98.4  
When the medication makes you feel sick, do you abandon it? 6 9.8 55 90.2  
Morisky-Green test Positive Negative  
 17 27.9 44 72.1  
Oral antineoplastic medication     0.022 
Imatinib - - 6 100.0  
Temozolamide - - 7 100.0  
Hormone therapy drugs 4 26.6 11 73.3  
Mercapturine 2 100.0 - -  
Capecitabine 8 38.1 13 61.9  
Erlotinib 2 33.3 4 66.6  
Others (Dexamethasone and Thalidomide) 1 25.0 3 75.0  
Treatment time (mean±SD, months) 27.3±40.5 9.5±13.9 0.008 
Table 4  Level of  agreement with attitudes and factors that may affect on treatment compliance to oral
antineoplastic
I completely 
agree (5) 
I partially 
agree(4) 
I AM 
indecisive (3) 
I partially 
disagree (2) 
I completely 
disagree (1) Factors and attitudes 
N  % N  % N  % N  % N  % 
1. Medication causes 
undesirable adverse effects 20 32.8 16 26.2 4 6.6 7 11.5 14 23.0 
2. I forget to take medication 3 4.9 7 11.5   3 4.9 48 78.7 
3. I need help to take 
medication 2 3.3 5 8.2 1 1.6 5 8.2 48 78.7 
4. I have to take a lot of 
medication 17 27.9 11 18.0 1 1.6 7 11.5 25 41.0 
5. I do not know how to take 
medication 1 1.6 2 3.3     58 95.1 
6. Oral treatment is 
complicated, difficult. 1 1.6   2 3.3 6 9.8 52 85.2 
7. I have difficulty to 
remember the day to resume 
medication  
4 6.6 2 3.3 1 1.6 4 6.6 50 82.0 
8. I have difficulty to buy 
medication  8 13.1 10 16.4   4 6.6 39 63.9 
9. I do not know whether I 
have to take medication 
before, during or after the 
meals 
3 4.9 5 8.2   6 9.8 47 77.0 
10. The medication is hard to 
swallow   7 11.5   3 4.9 51 83.6 
11. I forget to attend 
consultations.   1 1.6   1 1.6 59 96.7 
12. Oral medication 
treatments causes fewer job 
absences 
24 39.3 11 18.0 6 9.8 5 8.2 15 24.6 
13. The health team has 
helped with oral medication 
treatment 
30 49.2 10 16.4 6 9.8 1 1.6 14 23.0 
14. I have specific hours to 
take medication 48 78.7 10 16.4 2 3.3   1 1.6 
15. I check name and dosage 
before taking the medication 53 86.9 3 4.9   3 4.9 2 3.3 
16. I store the medication in 
an appropriate place 56 91.8 4 6.6 1 1.6     
17. I take the medication even 
when I feel sick 47 77.0 8 13.1 2 3.3 2 3.3 2 3.3 
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Table 5  Variables with significant statistical association with factors that may affect treatment compliance
 
Forgets to take medication 
Variables / Factors, attitudes 
Yes No 
p 
value 
Massage N % N % 0,032 
Yes  4 44.4 5 55.5  
No 6 11.5 46 88.4  
Has difficulty to remember the day to resume oral treatment      
Radiotherapy     0.03 
No 5 20.0 20 80.0  
Yes 1 2.7 35 97.2  
Has difficulty to buy oral medication      
Radiotherapy     0.03 
Yes 7 19.4 29 80.5  
No 11 44.0 14 56.0  
The health team has helped with oral medication treatment      
Medication     0.04 
Imatinib 1 16.6 5 83.3  
Temozolamide - - 7 100.0  
Hormone therapy drugs* 7 46.6 8 53.3  
Mercaptopurine - 0.0 2 100.0  
Capecitabine 4 19.1 17 80.9  
Erlotinib 3 50.0 3 50.0  
Others (Thalidomide/Dexamethasone) - - 4 100.0  
 Treatment 
difficulty <35 
Treatment 
difficulty >35 
 
Oral treatment time (mean±SD, months) 5.9±7.5 18.3±27.2 0.03 
(80%). They did not abandon medication, not even when
they did not feel well (90%), which are compatible
answers with Morisky and Green Test.
The factors or attitudes that may affect the treatment
and, eventually, compliance had a significant association
(p<0.05), with the following variables: alternative
treatment as massage, radiotherapy, treatment time and
type of antineoplastic medication. Considering patients
who did not get massages (n=51), most of them (88.4%)
did not forget to take the medication. Among the
patients who had radiotherapy (n=36), nearly all of them
(97.2%), did not have difficulty in remembering the day
when they had resumed treatment with oral medication.
They did not mention difficulty in buying medication
either (80%). All the patients using Temozolamide and
Mercaptopurine reported the lack of health team
support regarding treatment. Concerning other drugs,
patients referred to health professionals lack of support.
Treatment time with oral antineoplastics also had a
significant association with the obtained score in the
instrument that evaluated the hindrance factors during
treatment. Patients who showed higher scores (>35),
thus, with more difficulty in relation to oral antineoplastic
treatment, were being treated for longer (Table 5).
DISCUSSION
The main finding in the present study suggested that
treatment compliance to oral antineoplastic drugs in
cancer patients under ambulatory treatment was not total
when analyzed by the Morisky-Green Test. In this
evaluation instrument, the medication hours and patients
health status were pointed out as barriers for taking
medications, since all patients were seen to be careless
regarding schedules. Depending on the case, some
patients would quit using medication. Likewise, the
analysis through the specific instrument of factors and
attitudes when it comes to drug treatment also indicated
negative aspects such as forgetting to take medication,
which compromises treatment compliance.
Analyzing the compliance behavior is required in order
to plan effective treatment and guarantee that the
recommendations are followed. No formulas are able
to measure compliance behavior, but a combination of
varied strategies may aid the nursing practice, regarding
chronic diseases. A method chosen to evaluate the
behavior in the studied patients was with positive values
for Morisky-Green test. It was initially used with
hypertensive patients, but it can also be used with
oncologic patients. The authors recommend the test in
other contexts and other health problems(9). Patients with
cancer show characteristics similar to hypertensive
patients regarding disease chronicity, naturally prolonged,
long asymptomatic course, clinical manifestations with
remission and exacerbation periods, and evolution to
varied incapacity levels or death.
Indeed, the test also showed association with
interfering variables in the treatment compliance such as
the type of  antineoplastic drug. Except for patients using
Imatinibe and Temozolamide, all the others who were
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